PFO
ABUS icon

Pathstone Family Office’s Arbutus Biopharma ABUS Stock Holding History

Pathstone Family Office’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$20.3K Hold
10,000
– – ﹤0.01% 1647
2023
Q2 		$23K Hold
10,000
– – ﹤0.01% 1228
2023
Q1 		$30.3K Sell
10,000
-10,000
-50% -$28.2K ﹤0.01% 1169
2022
Q4 		$57.6K Hold
20,000
– – ﹤0.01% 1458
2022
Q3 		$38.1K Buy
20,000
+10,000
+100% +$23.5K ﹤0.01% 1451
2022
Q2 		$27.1K Hold
10,000
– – ﹤0.01% 1030
2022
Q1 		$30K Buy
+10,000
New +$30.6K ﹤0.01% 949

Other funds holding ABUS

WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pathstone Family Office's ABUS Position: Q3 2023 in Review

Pathstone Family Office held its Arbutus Biopharma (ABUS) position steady in Q3 2023 at 10,000 shares worth $20.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1647.

Pathstone Family Office first reported a position in ABUS in Q1 2022 and has held it in 7 quarters since. The position peaked at $57.6K in Q4 2022. 99 funds tracked by Wall St. Rank hold ABUS as of Q3 2023.

  • Pathstone Family Office held 10,000 shares of Arbutus Biopharma worth $20.3K as of Q3 2023.
  • Pathstone Family Office left its Arbutus Biopharma share count unchanged in Q3 2023.
  • Arbutus Biopharma made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1647 holding.
  • Pathstone Family Office first reported a position in Arbutus Biopharma in Q1 2022 and has held it in 7 quarters since.
  • Pathstone Family Office's Arbutus Biopharma position peaked at $57.6K in Q4 2022.
  • 99 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.